Research Pipeline

Molecule Indication MoA/Class
Pre-Clinical Phase 1 Phase 2 Phase 3 Approval
GBR 1302 HER2 positive cancers such as Breast Cancer and Gastric Cancer HER2xCD3 (bispecific mAb)
+
Oncology
GBR 1342 Multiple myeloma CD38xCD3 (bispecific mAb)
+
Oncology
GBR 1372 Colorectal Cancer EGFRxCD3 (bispecific mAb)
+
Oncology
GBR 830 Atopic dermatitis OX40 Antagonist (mAb)
+
Dermatology
GRC 39815 COPD, IPF ROR γ t inhibitor
+
Respiratory
Ryaltris™ (GSP 301) Allergic Rhinitis Steroid + AH
+
Respiratory
GSP 304 COPD LAMA
+
Respiratory
GBR 310 Asthma, CIU Biosimilar
+
Respiratory

Non-core assets include GRC 17536, GBR 900 and GBR 500. These 3 molecules and GRC 27864 are candidates for out-licensing.

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future
Know More